Blog

U.S. stock markets have had a choppy start to 2026, with investors balancing resilient economic data and AI-driven optimism against higher oil prices, sticky inflation risks, elevated Treasury

Amgen AMGN announced positive top-line results from a late-stage study evaluating the subcutaneous (under the skin or SC) formulation of its blockbuster drug Tepezza (teprotumumab) in patients with

Medifast, Inc. MED is shifting from a traditional weight-loss focus toward a broader metabolic health strategy. A national survey cited by the company found that nearly 94% of American adults are

JetBlue AirwaysJBLU is raising checked bag fees to respond to intense cost pressures caused by surging fuel prices, driven in part by the Iran conflict. As jet fuel remains one of the largest

Astera Labs ALAB is riding on strong demand for its Scorpio product family, which has become a significant driver of its revenue growth. The Scorpio family, comprising the P-Series and X-Series, is

Teradyne TER is benefiting from the accelerating growth of data centers, driven by the increasing demand for AI-driven applications and high-performance computing. In the fourth quarter of 2025

Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter fiscal 2026 performance and strategic

Franklin Resources, Inc. BEN reported its preliminary assets under management (AUM) of $1.68 trillion as of March 31, 2026, which decreased 3.1% from the prior month.

The decline in the AUM balance

Rigetti Computing RGTI continues to deepen its foothold in the emerging quantum computing ecosystem with the sale of its 9-qubit Novera QPU to the University of Saskatchewan (USask). The system will

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With

• Shares of Soleno Therapeutics, Inc. (SLNO) surged 32.3% after Neurocrine Biosciences, Inc. (NBIX) agreed to buy the drugmaker for $2.9 billion, or $53 per share in cash.
• Shares of Micron

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side)